Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease

References

• Agniswamy, J., Kneller, D. W., Brothers, R., Wang, Y.-F., Harrison, R. W., & Weber, I. T. (2019). Highly drug-resistant HIV-1 protease mutant PRS17 shows enhanced binding to substrate analogues. ACS Omega, 4(5), 8707–8719. https://doi.org/10.1021/acsomega.9b00683
   PubMed Web of Science ®Google Scholar
• Agniswamy, J., Louis, J. M., Shen, C.-H., Yashchuk, S., Ghosh, A. K., & Weber, I. T. (2015). Substituted Bis-THF protease inhibitors with improved potency against highly resistant mature HIV-1 protease PR20. Journal of Medicinal Chemistry, 58(12), 5088–5095. https://doi.org/10.1021/acs.jmedchem.5b00474
   PubMed Web of Science ®Google Scholar
• Agniswamy, J., Shen, C.-H., Wang, Y.-F., Ghosh, A. K., Rao, K. V., Xu, C.-H., Sayer, J. M., Louis, J. M., & Weber, I. T. (2013). Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran. Journal of Medicinal Chemistry, 56(10), 4017–4027. https://doi.org/10.1021/jm400231v
   PubMed Web of Science ®Google Scholar
• Arthur, D. E., & Uzairu, A. (2019). Molecular docking studies on the interaction of NCI anticancer analogues with human phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit. Journal of King Saud University, Science, 31, 1151–1166. https://doi.org/10.1016/j.jksus.2019.01.011
   Google Scholar
• Atkins, P., & de Paula, J. (2006). Physical chemistry for the life sciences (2nd ed., pp. 1–618). W.H. Freeman and Company.
   Google Scholar
• Bharat, T. A. M., Menendez, L. R. C., Hagen, W. J. H., Lux, V., Igonet, S., Schorb, M., Schur, F. K. M., Kräusslich, H.-G., & Briggs, J. A. G. (2014). Cryo-electron microscopy of tubular arrays of HIV-1 Gag resolves structures essential for immature virus assembly. Proceedings of the National Academy of Sciences of the United States of America, 22, 8233–8238.
   Google Scholar
• Boender, T. S., Hamers, R. L., Ondoa, P., Wellington, M., Chimbetete, C., Siwale, M., Maksimos, E. E. F. L., Balinda, S. N., Kityo, C. M., Adeyemo, T. A., Akanmu, A. S., Mandaliya, K., Botes, M. E., Stevens, W., Rinke de Wit, T. F., & Sigaloff, K. C. E. (2016). Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in Sub-Saharan Africa. Journal of Infectious Diseases, 214(6), 873–883. https://doi.org/10.1093/infdis/jiw219
   PubMed Web of Science ®Google Scholar
• Borman, A. M., Paulous, S., & Clavel, F. (1996). Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug. Journal of General Virology, 77(3), 419–426. https://doi.org/10.1099/0022-1317-77-3-419
   PubMedGoogle Scholar
• Brenk, R., Vetter, S. W., Boyce, S. E., Goodin, D. B., & Shoichet, B. K. (2006). Probing molecular docking in a charged model binding site. Journal of Molecular Biology, 357(5), 1449–14470. https://doi.org/10.1016/j.jmb.2006.01.034
   PubMed Web of Science ®Google Scholar
• Case, D. A., Babin, V., Berryman, J. T., Betz, R. M., Cai, Q., Cerutti, D. S., Cheatham, T. E., III, Darden, T. A., Duke, R. E., Gohlke, H., Goetz, A. W., Gusarov, S., Homeyer, N., Janowski, P., Kaus, J., Kolossváry, I., Kovalenko, A., Lee, T. S., LeGrand, S., … Kollman, P. A. (2014). AMBER 14. University of California.
   Google Scholar
• Chen, D., Oezguen, N., Urvil, P., Ferguson, C., Dann, S. M., & Savidge, T. C. (2016). Regulation of protein-ligand binding affinity by hydrogen bond pairing. Science Advances, 2(3), e1501240. https://doi.org/10.1126/sciadv.1501240
   PubMed Web of Science ®Google Scholar
• Chen, J. M., Xu, S. L., Wawrzak, Z., Basarab, G. S., & Jordan, D. B. (1998). Structure-based design of potent inhibitors of scytalone dehydratase: Displacement of a water molecule from the active site. Biochemistry, 37(51), 17735–17744. https://doi.org/10.1021/bi981848r
   PubMed Web of Science ®Google Scholar
• Dam, E., Quercia, R., Glass, B., Descamps, D., Launay, O., Duval, X., Kräusslich, H.-G., Hance, A. J., & Clavel, F. (2009). Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathogens, 5(3), e1000345. https://doi.org/10.1371/journal.ppat.1000345
   PubMed Web of Science ®Google Scholar
• Darden, T., York, D., & Pedersen, L. (1993). Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems. Journal of Chemical Physics, 98(12), 10089–10092. https://doi.org/10.1063/1.464397
   Web of Science ®Google Scholar
• Fehér, A., Weber, I. T., Bagossi, P., Boross, P., Mahalingam, B., Louis, J. M., Copeland, T. D., Torshin, I. Y., Harrison, R. W., & Tözsér, J. (2002). Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. European Journal of Biochemistry, 269(16), 4114–4120. https://doi.org/10.1046/j.1432-1033.2002.03105.x
   PubMedGoogle Scholar
• Fun, A., Wensing, A. M. J., Verheyen, J., & Nijhuis, M. (2012). Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology, 9, 63. https://doi.org/10.1186/1742-4690-9-63
   PubMed Web of Science ®Google Scholar
• Giandhari, J., Basson, A. E., Coovadia, A., Kuhn, L., Abrams, E. J., Strehlau, R., Morris, L., & Hunt, G. M. (2015). Genetic changes in HIV-1 Gag-protease associated with protease inhibitor-based therapy failure in pediatric patients. AIDS Research and Human Retroviruses, 31(8), 776–782. https://doi.org/10.1089/AID.2014.0349
   PubMed Web of Science ®Google Scholar
• Goodchild, S. C., Curmi, P. M. G., & Brown, L. J. (2011). Structural gymnastics of multifunctional metamorphic proteins. Biophysical Reviews, 3(3), 143. https://doi.org/10.1007/s12551-011-0053-8
   PubMedGoogle Scholar
• Gupta, R. K., Kohli, A., McCormick, A. L., Towers, G. J., Pillay, D., & Parry, C. M. (2010). Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS (London, England), 24(11), 1651–1655. https://doi.org/10.1097/qad.0b013e3283398216
   PubMed Web of Science ®Google Scholar
• Haspel, N., Moll, M., Baker, M. L., Chiu, W., & Kavraki, L. E. (2010). Tracing conformational changes in proteins. BMC Structural Biology, 10(Suppl 1), S1. https://doi.org/10.1186/1472-6807-10-S1-S1
   PubMedGoogle Scholar
• Ho, S. K., Coman, R. M., Bunger, J. C., Rose, S. L., O'Brien, P., Munoz, I., Dunn, B. M., Sleasman, J. W., & Goodenow, M. M. (2008). Drug-associated changes in amino acid residues in Gag p2, p7NC, and p6Gag/p6Pol in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology, 378(2), 272–281. https://doi.org/10.1016/j.virol.2008.05.029
   PubMed Web of Science ®Google Scholar
• Hou, T., Zhang, W., Wang, J., & Wang, W. (2009). Predicting drug resistance of the HIV-1 protease using molecular interaction energy components. Proteins, 74(4), 837–846. https://doi.org/10.1002/prot.22192
   PubMed Web of Science ®Google Scholar
• Hu, L., Huang, T., Liu, X.-J., & Cai, Y.-D. (2011). Predicting protein phenotypes based on protein-protein interaction network. PLoS One, 6(3), e17668. https://doi.org/10.1371/journal.pone.0017668
   PubMed Web of Science ®Google Scholar
• Huggins, D. J., & Tidor, B. (2011). Systematic placement of structural water molecules for improved scoring of protein-ligand interactions. Protein Engineering, Design & Selection: PEDS, 24(10), 777–789. https://doi.org/10.1093/protein/gzr036
   PubMed Web of Science ®Google Scholar
• Kantor, R., Zijenah, L. S., Shafer, R. W., Mutetwa, S., Johnston, E., Lloyd, R., von Lieven, A., Israelski, D., & Katzenstein, D. A. (2002). HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Research and Human Retroviruses, 18(18), 1407–1413. https://doi.org/10.1089/088922202320935483
   PubMed Web of Science ®Google Scholar
• Kennedy, D. A., & Read, A. F. (2017). Why does drug resistance readily evolve but vaccine resistance does not? Proceedings of the Royal Society B: Biological Sciences, 284(1851), 20162562. https://doi.org/10.1098/rspb.2016.2562
   PubMed Web of Science ®Google Scholar
• Kiguoya, M. W., Mann, J. K., Chopera, D., Gounder, K., Lee, G. Q., Hunt, P. W., Martin, J. N., Ball, T. B., Kimani, J., Brumme, Z. L., Brockman, M. A., & Ndung’u, T. (2017). Subtype-specific differences in Gag- protease-driven replication capacity are consistent with intersubtype differences in HIV-1 disease progression. Journal of Virology, 91, e00253.
   PubMed Web of Science ®Google Scholar
• King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A., & Schiffer, C. A. (2004). Combating susceptibility to drug resistance: Lessons from HIV-1 protease. Chemistry & Biology, 11(10), 1333–1338. https://doi.org/10.1016/j.chembiol.2004.08.010
   PubMedGoogle Scholar
• Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D. A., & Cheatham, I. I T. (2000). Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33(12), 889–897. [Database] https://doi.org/10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Liu, F., Kovalevsky, A. Y., Tie, Y., Ghosh, A. K., Harrison, R. W., & Weber, I. T. (2008). Effect of flap mutations on structure of HIV-1 protease and inhibition by Saquinavir and Darunavir. Journal of Molecular Biology, 381(1), 102–115. https://doi.org/10.1016/j.jmb.2008.05.062
   PubMed Web of Science ®Google Scholar
• Louis, J. M., Zhang, Y., Sayer, J. M., Wang, Y.-F., Harrison, R. W., & Weber, I. T. (2011). The L76V drug resistance mutation decreases the dimer stability and rate of autoprocessing of HIV-1 protease by reducing internal hydrophobic contacts. Biochemistry, 50(21), 4786–4795. https://doi.org/10.1021/bi200033z
   PubMed Web of Science ®Google Scholar
• Lv, Z., Cju, Y., & Wang, Y. (2015). HIV protease inhibitors: A review of molecular selectivity and toxicity. HIV/AIDS Research and Palliative Care, 7, 95–104.
   Google Scholar
• Malet, I., Roquebert, B., Dalban, C., Wirden, M., Amellal, B., Agher, R., Simon, A., Katlama, C., Costagliola, D., Calvez, V., & Marcelin, A. G. (2007). Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. Journal of Infection, 54(4), 367–374. https://doi.org/10.1016/j.jinf.2006.06.012
   PubMed Web of Science ®Google Scholar
• Marie, V., & Gordon, M. (2019). Gag-protease coevolution shapes the outcome of lopinavir-inclusive treatment regimens in chronically infected HIV-1 subtype C patients. Bioinformatics (Oxford, England), 35(18), 3219–3223. https://doi.org/10.1093/bioinformatics/btz076
   PubMed Web of Science ®Google Scholar
• Nakashima, M., Ode, H., Suzuki, K., Fujino, M., Maejima, M., Kimura, Y., Masaoka, T., Hattori, J., Matsuda, M., Hachiya, A., Yokomaku, Y., Suzuki, A., Watanabe, N., Sugiura, W., & Iwatani, Y. (2016). Unique flap conformation in an HIV-1 protease with high-level darunavir resistance. Frontiers in Microbiology, 7, 61. https://doi.org/10.3389/fmicb.2016.00061
   PubMed Web of Science ®Google Scholar
• Nguyen, Q. H., Contamin, L., Nguyen, T. V. A., & Bañuls, A.-L. (2018). Insights into the processes that drive the evolution of drug resistance in Mycobacterium tuberculosis. Evolutionary Applications, 11(9), 1498–1511. https://doi.org/10.1111/eva.12654
   PubMed Web of Science ®Google Scholar
• Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S., & Boucher, C. A. (1999). Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS (London, England), 13(17), 2349–2359. https://doi.org/10.1097/00002030-199912030-00006
   PubMed Web of Science ®Google Scholar
• Nijhuis, M., van Maarseveen, N. M., Lastere, S., Schipper, P., Coakley, E., Glass, B., Rovenska, M., de Jong, D., Chappey, C., Goedegebuure, I. W., Heilek-Snyder, G., Dulude, D., Cammack, N., Brakier- Gingras, L., Konvalinka, J., Parkin, N., Kräusslich, H.-G., Brun-Vezinet, F., & Boucher, C. A. B. (2007). A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Medicine, 4(1), e36. https://doi.org/10.1371/journal.pmed.0040036
   PubMed Web of Science ®Google Scholar
• Ning, J., Erdemci-Tandogan, G., Yufenyuy, E. L., Wagner, J., Himes, B. A., Zhao, G., Aiken, C., Zandi, R., & Zhang, P. (2016). In vitro protease cleavage and computer simulations reveal the HIV-1 capsid maturation pathway. Nature Communications, 7, 13689. https://doi.org/10.1038/ncomms13689
   PubMed Web of Science ®Google Scholar
• Özen, A., Haliloğlu, T., & Schiffer, C. A. (2011). Dynamics of preferential substrate recognition in HIV-1 protease: Redefining the substrate envelope. Journal of Molecular Biology, 410(4), 726–744. https://doi.org/10.1016/j.jmb.2011.03.053
   PubMed Web of Science ®Google Scholar
• Paredes, R., Tzou, P. L., van Zyl, G., Barrow, G., Camacho, R., Carmona, S., Grant, P. M., Gupta, R. K., Hamers, R. L., Harrigan, P. R., Jordan, M. R., Kantor, R., Katzenstein, D. A., Kuritzkes, D. R., Maldarelli, F., Otelea, D., Wallis, C. L., Schapiro, J. M., & Shafer, R. W. (2017). Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS One, 12(7), e0181357. https://doi.org/10.1371/journal.pone.0181357
   PubMed Web of Science ®Google Scholar
• Parry, C. M., Kohli, A., Boinett, C. J., Towers, G. J., McCormick, A. L., & Pillay, D. (2009). Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. Journal of Virology, 83(18), 9094–9101. https://doi.org/10.1128/JVI.02356-08
   PubMed Web of Science ®Google Scholar
• Porter, L. L., & Looger, L. L. (2018). Extant fold-switching proteins are widespread. Proceedings of the National Academy of Sciences of the United States of America, 115(23), 5968–5973. https://doi.org/10.1073/pnas.1800168115
   PubMed Web of Science ®Google Scholar
• Prado, J. G., Wrin, T., Beauchaine, J., Ruiz, L., Petropoulos, C. J., Frost, S. D. W., Clotet, B., D'Aquila, R. T., & Martinez-Picado, J. (2002). Amprenavir-resistant HIV-1 exhibits Lopinavir cross-resistance and reduced replication capacity. AIDS (London, England), 16(7), 1009–1017. https://doi.org/10.1097/00002030-200205030-00007
   PubMed Web of Science ®Google Scholar
• Ragland, D. A., Nalivaika, E. A., Nalam, M. N. L., Prachanronarong, K. L., Cao, H., Bandaranayake, R. M., Cai, Y., Kurt-Yilmaz, N., & Schiffer, C. A. (2014). Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. Journal of the American Chemical Society, 136(34), 11956–11963. https://doi.org/10.1021/ja504096m
   PubMed Web of Science ®Google Scholar
• Raugi, D. N., Smith, R. A., & Gottlieb, G. S. (2016). Four amino acid changes in HIV-2 protease confer class-wide sensitivity to protease inhibitors. Journal of Virology, 90(2), 1062–1069. https://doi.org/10.1128/JVI.01772-15
   PubMed Web of Science ®Google Scholar
• Rhee, S. Y., Gonzales, M. J., Kantor, R., Betts, B. J., Ravela, J., & Shafer, R. W. (2003). Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research, 31(1), 298–303. https://doi.org/10.1093/nar/gkg100
   PubMed Web of Science ®Google Scholar
• Ryckaert, J.-P., Ciccotti, G., & Berendsen, H. J. C. (1977). Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-Alkanes. Journal of Computational Physics, 23(3), 327–341. https://doi.org/10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Su, C. T.-T., Kwoh, C.-K., Verma, C. S., & Gan, S. K.-E. (2018). Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance. Journal of Biomolecular Structure & Dynamics, 36(16), 4366–4377. https://doi.org/10.1080/07391102.2017.1417160
   PubMed Web of Science ®Google Scholar
• Sundquist, W. I., & Kräusslich, H.-G. (2012). HIV-1 assembly, budding, and maturation. Cold Spring Harbor Perspectives in Medicine, 2(7), a006924. https://doi.org/10.1101/cshperspect.a006924
   PubMed Web of Science ®Google Scholar
• Teto, G., Tagny, C. T., Mbanya, D., Fonsah, J. Y., Fokam, J., Nchindap, E., Kenmogne, L., Njamnshi, A. K., & Kanmogne, G. D. (2017). Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG infected patients in Yaoundé, Cameroon. Scientific Reports, 7, 14136.
   PubMed Web of Science ®Google Scholar
• Verheyen, J., Litau, E., Sing, T., Däumer, M., Balduin, M., Oette, M., Fätkenheuer, G., Rockstroh, J. K., Schuldenzucker, U., Hoffmann, D., Pfister, H., & Kaiser, R. (2006). Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antiviral Therapy, 11, 879–887.
   PubMed Web of Science ®Google Scholar
• Weber, I. T., & Agniswamy, J. (2009). HIV-1 protease: Structural perspectives on drug resistance. Viruses, 1(3), 1110–1136. https://doi.org/10.3390/v1031110
   PubMed Web of Science ®Google Scholar
• Wensing, A. M., Calvez, V., Günthard, H. F., Johnson, V. A., Paredes, R., Pillay, D., Shafer, R. W., & Richman, D. D. (2016). 2017 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 24(4), 132–133.
   PubMedGoogle Scholar
• Williams, A., Basson, A., Achilonu, I., Dirr, H. W., Morris, L., & Sayed, Y. (2019). Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility. The Biochemical Journal, 476(2), 375–384. https://doi.org/10.1042/BCJ20180692
   PubMedGoogle Scholar
• Wong-Sam, A., Wang, Y.-F., Zhang, Y., Ghosh, A. K., Harrison, R. W., & Weber, I. T. (2018). Drug resistance mutation L76V alters nonpolar interactions at the flap-core interface of HIV-1 protease. ACS Omega, 3(9), 12132–12140. https://doi.org/10.1021/acsomega.8b01683
   PubMed Web of Science ®Google Scholar
• Young, T. P., Parkin, N. T., Stawiski, E., Pilot-Matias, T., Trinh, R., Kempf, D. J., & Norton, M. (2010). Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease. Antimicrobial Agents and Chemotherapy, 54(11), 4903–4906. https://doi.org/10.1128/AAC.00906-10
   PubMed Web of Science ®Google Scholar
• Yu, Y., Wang, J., Shao, Q., Shi, J., & Zhu, W. (2015). Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir. Scientific Reports, 5, 10517.
   PubMed Web of Science ®Google Scholar